Neha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the ​phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.

Recent updated data from the CASSIOPEIA study have highlighted the results of a minimal residual disease (MRD) analysis for patients with previously untreated multiple myeloma, Korde says. The findings show that patients who received daratumumab (Darzalex) plus bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd) tended to have higher rates of MRD compared with patients who received VTd alone, as well as sustained MRD negativity if patients were in a complete response or a stringent complete response, Korde explains.

Moreover, looking to the future, study updates are anticipated to see how MRD-negative rates affect progression-free survival, especially when looking at the maintenance setting for patients with multiple myeloma, Korde concludes.

Videos

Neha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the ​phase 3 Cassiopeia study (NCT02541383) in multiple myeloma. 

Neha S. Korde, MD

Articles

Dr. Korde on Updated Findings From the Cassiopeia Trial in Multiple Myeloma